Table 4.

The Western blot quantification results in IC/BPS patients with different treatment outcome groups

Biomarker	Time point	GRA=0 (n=3)	GRA≥1 (n=16)	P-value†	ΔVAS <1 (n=6)	ΔVAS ≥ 1 (n=13)	P-value†	ΔFBC< 25% (n=7)	ΔFBC≥25% (n=12)	P-value†
Shh	Baseline	0.29 ± 0.29	0.18 ± 0.25	0.716	0.24 ± 0.22	0.18 ± 0.27	0.611	0.26 ± 0.39	0.16 ± 0.16	0.345
	After PRP	0.34 ± 0.22	0.33 ± 0.26*		0.40 ± 0.34	0.30 ± 0.21*		0.45 ± 0.31	0.26 ± 0.19*
CD34	Baseline	1.09 ± 0.68	0.58 ± 0.32	0.342	0.90 ± 0.57	0.54 ± 0.26	0.688	0.89 ± 0.52	0.58 ± 0.36	0.158
	After PRP	0.75 ± 0.40	0.56 ± 0.30		0.84 ± 0.34	0.45 ± 0.19		0.57 ± 0.27	0.63 ± 0.37
CK5	Baseline	0.78 ± 0.85	0.64 ± 1.09	0.793	0.68 ± 0.73	0.67 ± 1.15	0.585	1.22 ± 1.80	0.46 ± 0.47	0.642
	After PRP	0.71 ± 0.63	0.85 ± 0.53		1.05 ± 0.84	0.75 ± 0.35		1.02 ± 0.63	0.69 ± 0.40
CK14	Baseline	0.52 ± 0.36	0.31 ± 0.28	0.490	0.31 ± 0.29	0.43 ± 0.31	0.962	0.44 ± 0.41	0.30 ± 0.22	0.781
	After PRP	0.28 ± 0.30	0.44 ± 0.39		0.38 ± 0.35	0.54 ± 0.46		0.54 ± 0.38	0.36 ± 0.38
CK20	Baseline	0.57 ± 0.36	0.16 ± 0.19	0.925	0.19 ± 0.21	0.34 ± 0.37	0.380	0.11 ± 0.11	0.29 ± 0.30	0.043
	After PRP	0.29 ± 0.34	0.14 ± 0.27		0.08 ± 0.06	0.35 ± 0.47		0.31 ± 0.43	0.08 ± 0.05*
ZO-1	Baseline	0.12 ± 0.02	0.17 ± 0.09	0.768	0.12 ± 0.05	0.18 ± 0.09	0.347	0.11 ± 0.05	0.19 ± 0.09	0.233
	After PRP	0.36 ± 0.09	0.49 ± 0.30*		0.57 ± 0.39	0.44 ± 0.25*		0.57 ± 0.33*	0.43 ± 0.26*
E-cad	Baseline	0.35 ± 0.42	0.48 ± 0.45	0.439	0.50 ± 0.31	0.44 ± 0.50	0.815	0.60 ± 0.68	0.38 ± 0.20	0.071
	After PRP	0.66 ± 0.46	0.68 ± 0.56*		0.74 ± 0.38	0.65 ± 0.61*		0.94 ± 0.74*	0.52 ± 0.32*
TGF-β	Baseline	0.82 ± 0.83	0.25 ± 0.25	0.098	0.59 ± 0.69	0.25 ± 0.25	0.045	0.58 ± 0.71	0.25 ± 0.24	0.749
	After PRP	0.97 ± 0.57	0.75 ± 0.21*		0.81 ± 0.38	0.77 ± 0.23*		0.84 ± 0.28	0.73 ± 0.26*
ICAM-1	Baseline	2.73 ± 3.93	1.70 ± 1.87	0.048	2.92 ± 3.19	1.52 ± 1.89	0.037	1.84 ± 3.06	1.97 ± 1.96	0.818
	After PRP	2.15 ± 0.00	0.73 ± 0.61		1.26 ± 0.83	0.72 ± 0.66		0.96 ± 0.92	0.75 ± 0.49
Mast cell	Baseline	1.06 ± 0.32	1.68 ± 4.53	0.995	0.82 ± 0.59	1.93 ± 5.01	0.399	3.12 ± 6.83	0.68 ± 0.40	0.355
	After PRP	0.68 ± 0.59	1.28 ± 1.54		1.28 ± 0.79	1.14 ± 1.69		1.90 ± 2.18	0.77 ± 0.54

Values are presented as mean±standard deviation.

IC/BPS, interstitial cystitis/bladder pain syndrome; GRA, global response assessment; VAS, visual analogue scale; FBC, functional bladder capacity; Shh, sonic hedgehog; PRP, platelet-rich plasma; CK, cytokeratin; ZO-1, zonula occludens-1; E-cad, E-cadherin; TGF-β, transforming growth factor-β; ICAM-1, intercellular adhesive molecule-1.

^*P<0.05 in paired t-test. Comparing the urothelial protein expression in baseline and after PRP treatment within each group.

^†P-value analyzed by comparing the changes of urothelial protein expression between different treatment outcome groups (independent t-test).